

参考文献:

- [1] CHAKER L, COOPER DS, WALSH JP, et al. Hyperthyroidism[J]. Lancet, 2024, 403(10428): 768-780. DOI: 10.1016/S0140-6736(23)02016-0.
- [2] LEE SY, PEARCE EN. Hyperthyroidism: A review[J]. JAMA, 2023, 330(15): 1472-1483. DOI: 10.1001/jama.2023.19052.
- [3] WIERSINGA WM, POPPE KG, EFFRAIMIDIS G. Hyperthyroidism: Aetiology, pathogenesis, diagnosis, management, complications, and prognosis[J]. Lancet Diabetes Endocrinol, 2023, 11(4): 282-298. DOI: 10.1016/S2213-8587(23)00005-0.
- [4] HOLLOWELL JG, STAEHLING NW, FLANDERS WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) [J]. J Clin Endocrinol Metab, 2002, 87(2): 489-499. DOI: 10.1210/jcem.87.2.8182.
- [5] GARMENDIA MADARIAGA A, SANTOS PALACIOS S, GUILLÉN-GRIMA F, et al. The incidence and prevalence of thyroid dysfunction in Europe: A meta-analysis[J]. J Clin Endocrinol Metab, 2014, 99(3): 923-931. DOI: 10.1210/jc.2013-2409.
- [6] WALSH JP. Managing thyroid disease in general practice[J]. Med J Aust, 2016, 205(4): 179-184. DOI: 10.5694/mja16.00545.
- [7] DU Y, GAO YH, MENG FG, et al. Iodine deficiency and excess coexist in China and induce thyroid dysfunction and disease: A cross-sectional study[J]. PLoS One, 2014, 9(11): e111937. DOI: 10.1371/journal.pone.0111937.
- [8] AGHINI-LOMBARDI F, ANTONANGELI L, MARTINO E, et al. The spectrum of thyroid disorders in an iodine-deficient community: The Pescopagano survey[J]. J Clin Endocrinol Metab, 1999, 84(2): 561-566. DOI: 10.1210/jcem.84.2.5508.
- [9] ROSS DS, BURCH HB, COOPER DS, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Thyroid, 2016, 26(10): 1343-1421. DOI: 10.1089/thy.2016.0229.
- [10] LI J, SHAN ZY. Current status and challenges of diagnosis and treatment of hyperthyroidism in China[J]. J Diagn Concepts Pract, 2024, 23(4): 347-353. DOI: 10.16150/j.1671-2870.2024.04.001.
李静, 单忠艳. 我国甲状腺功能亢进的诊治现状及挑战[J]. 诊断学理论与实践, 2024, 23(4): 347-353. DOI: 10.16150/j.1671-2870.2024.04.001.
- [11] PIANTANIDA E, IPPOLITO S, GALLO D, et al. The interplay between thyroid and liver: Implications for clinical practice[J]. J Endocrinol Invest, 2020, 43(7): 885-899. DOI: 10.1007/s40618-020-01208-6.
- [12] XIE CX, MACHADO GC. Clinimetrics: Grading of recommendations, assessment, development and evaluation (GRADE) [J]. J Physiother, 2021, 67(1): 66. DOI: 10.1016/j.jphys.2020.07.003.
- [13] ZHANG Y, AKL EA, SCHÜNEMANN HJ. Using systematic reviews in guideline development: The GRADE approach[J]. Res Synth Methods, 2019, 10(3): 1313. DOI: 10.1002/jrsm.1313.
- [14] LIN TY, SHEKAR AO, LI N, et al. Incidence of abnormal liver biochemical tests in hyperthyroidism[J]. Clin Endocrinol, 2017, 86(5): 755-759. DOI: 10.1111/cen.13312.
- [15] AYDEMIR S, BAYRAKTOĞLU T, DEMIRCAN N, et al. Effect of hyperthyroidism and propylthiouracil treatment on liver biochemical tests[J]. Int J Clin Pract, 2005, 59(11): 1304-1308. DOI: 10.1111/j.1368-5031.2005.00611.x.
- [16] KUBOTA S, AMINO N, MATSUMOTO Y, et al. Serial changes in liver function tests in patients with thyrotoxicosis induced by Graves' disease and painless thyroiditis[J]. Thyroid, 2008, 18(3): 283-287. DOI: 10.1089/thy.2007.0189.
- [17] SCAPPATICCIO L, LONGO M, MAIORINO MI, et al. Abnormal liver blood tests in patients with hyperthyroidism: Systematic review and meta-analysis[J]. Thyroid, 2021, 31(6): 884-894. DOI: 10.1089/thy.2020.0715.
- [18] ZHANG Y, XIA WF, YANG XL, et al. Clinical features and risk factors of liver injuries in patients with hyperthyroidism[J]. J Pract Hepatol, 2023, 26(2): 238-241. DOI: 10.3969/j.issn.1672-5069.2023.02.022.
- [19] CHEN ZF, SHAO HG, XIE KH. Causes and clinical characteristics of liver injury in 113 hyperthyroidism patients[J]. Chin Hepatol, 2024, 29(4): 457-460. DOI: 10.3969/j.issn.1008-1704.2024.04.021.
陈智峰, 邵挥戈, 谢开汉. 甲状腺功能亢进合并肝损伤的临床特征[J]. 肝脏, 2024, 29(4): 457-460. DOI: 10.3969/j.issn.1008-1704.2024.04.021.
- [20] WANG RF, TAN J, ZHANG GZ, et al. Risk factors of hepatic dysfunction in patients with Graves' hyperthyroidism and the efficacy of 131iodine treatment[J]. Medicine, 2017, 96(5): e6035. DOI: 10.1097/MD.00000000000006035.
- [21] WANG MT, LEE WJ, HUANG T, et al. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: A population-based cohort study[J]. Br J Clin Pharmacol, 2014, 78(3): 619-629. DOI: 10.1111/bcp.12336.
- [22] YU WS, WU N, LI L, et al. Side effects of ptu and mmi in the treatment of hyperthyroidism: A systematic review and meta-analysis[J]. Endocr Pract, 2020, 26(2): 207-217. DOI: 10.4158/EP-2019-0221.
- [23] SUZUKI N, NOH JY, HIRUMA M, et al. Analysis of antithyroid drug-induced severe liver injury in 18, 558 newly diagnosed patients with Graves' disease in Japan[J]. Thyroid, 2019, 29(10): 1390-1398. DOI: 10.1089/thy.2019.0045.
- [24] LI XS, YANG JL, JIN SS, et al. Mechanistic examination of methimazole-induced hepatotoxicity in patients with Grave's disease: A metabolomic approach[J]. Arch Toxicol, 2020, 94(1): 231-244. DOI: 10.1007/s00204-019-02618-z.
- [25] BEN AMARA I, HAKIM A, TROUDI A, et al. Protective effects of selenium on methimazole-induced Anemia and oxidative stress in adult rats and their offspring[J]. Hum Exp Toxicol, 2011, 30(10): 1549-1560. DOI: 10.1177/0960327110392403.
- [26] LI XS, JIN SS, FAN YJ, et al. Association of HLA-C*03: 02 with methimazole-induced liver injury in Graves' disease patients[J]. Biomed Pharmacother, 2019, 117: 109095. DOI: 10.1016/j.biopha.2019.109095.
- [27] JIN SS, LI XS, FAN YJ, et al. Association between genetic polymorphisms of SLCO1B1 and susceptibility to methimazole-induced liver injury[J]. Basic Clin Pharmacol Toxicol, 2019, 125(6): 508-517. DOI: 10.1111/bcpt.13284.
- [28] HE QF, LI M, JI PY, et al. Comparison of drug-induced liver injury risk between propylthiouracil and methimazole: A quantitative systems toxicology approach[J]. Toxicol Appl Pharmacol, 2024, 491: 117064. DOI: 10.1016/j.taap.2024.117064.
- [29] WANG BR, WANG BM, YANG YM, et al. Thyroid function and non-alcoholic fatty liver disease in hyperthyroidism patients[J]. BMC Endocr Disord, 2021, 21(1): 27. DOI: 10.1186/s12902-021-00694-w.
- [30] LU R, LIU Y, HONG TP. Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review[J]. Diabetes Obes Metab, 2023, 25(Suppl 1): 13-26. DOI: 10.1111/dom.15014.
- [31] JIANG W, LIU CH, WU DB, et al. Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: A population study in Sichuan[J]. Biosci Rep, 2021, 41(12): BSR20211769. DOI: 10.1042/BSR20211769.
- [32] BISHAY RH, CHEN RCY. Hashimoto's thyroiditis and Graves' disease in one patient: The extremes of thyroid dysfunction associated with interferon treatment[J]. Case Rep Endocrinol, 2016, 2016: 6029415. DOI: 10.1155/2016/6029415.
- [33] MAIGA I, VALDES-SOCIN H, THIRY A, et al. Alpha interferon induced hyperthyroidism: A case report and review of the literature [J]. Rev Med Liege, 2015, 70(7-8): 390-394.
- [34] HONG SE, CHOO JW, LIM SK, et al. A case of Graves' disease accompanied with acute hepatitis A virus infection[J]. Korean J Gastroenterol, 2018, 71(6): 354. DOI: 10.4166/kjg.2018.71.6.354.
- [35] KONG SJ, MIN SK, KIM IK, et al. Two cases of acute hepatitis E in patients with hyperthyroidism[J]. Korean J Gastroenterol, 2006, 47(1): 65-71.

- [36] CUI W, DENG BC, WANG W, et al. Graves' hyperthyroidism accompanied with acute hepatitis B virus infection: An extrahepatic manifestation? [J]. Virol J, 2016, 13: 80. DOI: 10.1186/s12985-016-0537-z.
- [37] HUANG D, ZHANG XH, TONG J, et al. Graves' disease and autoimmune liver diseases: One case report and literature review[J]. J Pract Hepatol, 2024, 27(1): 148-150. DOI: 10.3969/j.issn.1672-5069.2024.01.038.
黄蝶, 张鑫赫, 佟静, 等. Graves病合并自身免疫性肝病1例并文献复习[J]. 实用肝脏病杂志, 2024, 27(1): 148-150. DOI: 10.3969/j.issn.1672-5069.2024.01.038.
- [38] SATO T, KUMAGAI I, SUZUKI K, et al. Over 3-years follow-up of a case of primary biliary cholangitis with autoimmune hyperthyroidism: Factors associated with liver dysfunction[J]. Cureus, 2022, 14(12): e32941. DOI: 10.7759/cureus.32941.
- [39] GHASSA A, KILANI H, AL-SAYED S, et al. Systemic sclerosis associated with primary sclerosing cholangitis and hyperthyroidism: A case report[J]. Ann Med Surg, 2023, 85(6): 3031-3034. DOI: 10.1097/MS9.0000000000000727.
- [40] ZENG QM, ZHAO LL, WANG CY, et al. Relationship between autoimmune liver disease and autoimmune thyroid disease: A cross-sectional study[J]. Scand J Gastroenterol, 2020, 55(2): 216-221. DOI: 10.1080/00365521.2019.1710766.
- [41] CHEN S, LI MQ, DUAN WJ, et al. Concomitant extrahepatic autoimmune diseases do not compromise the long-term outcomes of primary biliary cholangitis[J]. Hepatobiliary Pancreat Dis Int, 2022, 21(6): 577-582. DOI: 10.1016/j.hbpd.2022.05.009.
- [42] KHOURY T, KADAH A, MARI A, et al. Thyroid dysfunction is prevalent in autoimmune hepatitis: A case control study[J]. Isr Med Assoc J, 2020, 22(2): 100-103.
- [43] LIU XQ, XU BM, ZENG YL, et al. Case report: Severe cholestatic jaundice associated with hyperthyroidism treated with methimazole[J]. Medicine, 2023, 102(45): e35972. DOI: 10.1097/md.00000000000035972.
- [44] LI C, TAN J, ZHANG G, et al. Risk factors of hyperthyroidism with hepatic function injury: A 4-year retrospective study[J]. Horm Metab Res, 2015, 47(3): 209-213. DOI: 10.1055/s-0034-1375690.
- [45] BURT AD, FERRELL LD, HÜBSCHER SG. Front matter[M]//MacSween's Pathology of the Liver. Amsterdam: Elsevier, 2024: iii. DOI: 10.1016/b978-0-7020-8228-3.00019-3.
- [46] KHAN AA, ATA F, AZIZ A, et al. Clinical characteristics and outcomes of patients with antithyroid drug-related liver injury[J]. J Endocr Soc, 2023, 8(1): bvad133. DOI: 10.1210/jeendo/bvad133.
- [47] GALLELLI L, STALTARI O, PALLERIA C, et al. Hepatotoxicity induced by methimazole in a previously healthy patient[J]. Curr Drug Saf, 2009, 4(3): 204-206. DOI: 10.2174/157488609789006912.
- [48] HADDADEN M, HANNA A, ODISH F, et al. Cholestatic hepatitis in Graves' disease: A diagnostic challenge[J]. ACG Case Rep J, 2021, 8(1): e00526. DOI: 10.14309/crj.0000000000000526.
- [49] LIAW YF, HUANG MJ, FAN KD, et al. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study[J]. Ann Intern Med, 1993, 118(6): 424-428. DOI: 10.7326/0003-4819-118-6-199303150-00005.
- [50] DI GREGORIO C, GHINI F, RIVASI F. Granulomatous hepatitis in a patient receiving methimazole[J]. Ital J Gastroenterol, 1990, 22(2): 75-77.
- [51] SATO I, TSUNEKAWA T, SHINOHARA Y, et al. A case of autoimmune hepatitis with Graves' disease treated by propylthiouracil[J]. Nagoya J Med Sci, 2011, 73(3-4): 205-209. DOI: 10.18999/NAGJMS.73.3-4.205.
- [52] OZENİRLER S, TUNCER C, BOZTEPE U, et al. Propylthiouracil-induced hepatic damage[J]. Ann Pharmacother, 1996, 30(9): 960-963. DOI: 10.1177/106002809603000909.
- [53] WEISS M. Propylthiouracil-induced hepatic damage[J]. Arch Intern Med, 1980, 140(9): 1184. DOI: 10.1001/archinte.1980.0033020006-0021.
- [54] MIYAKE T, MATSUURA B, FURUKAWA S, et al. Hyperthyroidism improves the pathological condition of nonalcoholic steatohepatitis: A case of nonalcoholic steatohepatitis with Graves' disease[J]. Intern Med, 2016, 55(15): 2019-2023. DOI: 10.2169/internalmedicine.55.6640.
- [55] CHENG N, ZHANG LL. Relationship between prognosis and hepatitis B virus infection of 45 hyperthyroidism patients with abnormal liver function[J]. Chin Hepatol, 2008, 13(2): 179-180. DOI: 10.14000/j.cnki.issn.1008-1704.2008.02.038.
程娜, 张伦理. 45例肝功能异常的甲状腺功能亢进患者预后与乙型肝炎病毒感染的关系[J]. 肝脏, 2008, 13(2): 179-180. DOI: 10.14000/j.cnki.issn.1008-1704.2008.02.038.
- [56] WENG WZ, CHEN JF, PENG XH, et al. Risk factors for underlying comorbidities and complications in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Epidemiol Infect, 2022, 150: e147. DOI: 10.1017/S0950268822001169.
- [57] SUAREZ-ZDUNEK MA, ARENTOFT NS, KROHN PS, et al. Prevalence of hyperthyroidism and hypothyroidism in liver transplant recipients and associated risk factors[J]. Sci Rep, 2024, 14(1): 7828. DOI: 10.1038/s41598-024-58544-3.
- [58] XU RY, TANG H, BAI L. Diagnosis and treatment of new-onset or uncontrolled hyperthyroidism-induced liver injury[J]. Chin J Hepatol, 2021, 29(10): 926-931. DOI: 10.3760/cma.j.cn501113-20210830-00439.
徐如意, 唐红, 白浪. 新发或未控制甲状腺功能亢进症导致肝损伤的诊断与治疗[J]. 中华肝脏病杂志, 2021, 29(10): 926-931. DOI: 10.3760/cma.j.cn501113-20210830-00439.
- [59] KIM SM, RYU V, MIYASHITA S, et al. Thyrotropin, hyperthyroidism, and bone mass[J]. J Clin Endocrinol Metab, 2021, 106(12): e4809-e4821. DOI: 10.1210/clinem/dgab548.
- [60] YANG RT, YANG R, DENG X, et al. Diagnosis and treatment principles of liver injury induced by antithyroid drugs[J]. J Clin Hepatol, 2024, 40(3): 621-625. DOI: 10.12449/JCH240331.
杨睿涛, 杨锐, 邓勋, 等. 抗甲状腺药物所致肝损伤的诊断与治疗原则[J]. 临床肝胆病杂志, 2024, 40(3): 621-625. DOI: 10.12449/JCH240331.
- [61] MAO YM, MA SW, LIU CH, et al. Chinese guideline for the diagnosis and treatment of drug-induced liver injury: An update[J]. Hepatol Int, 2024, 18(2): 384-419. DOI: 10.1007/s12072-023-10633-7.
- [62] CHEN H, GAO SQ, XIAO JR, et al. Clinical analysis of drug-induced liver damage caused by Huangyaozi (*Dioscorea bulbifera* L.) and its preparation[J]. J Hunan Univ Chin Med, 2021, 41(9): 1442-1446. DOI: 10.3969/j.issn.1674-070X.2021.09.023.
陈红, 高水群, 肖锦仁, 等. 黄药子及其制剂致药物性肝损伤病例临床分析[J]. 湖南中医药大学学报, 2021, 41(9): 1442-1446. DOI: 10.3969/j.issn.1674-070X.2021.09.023.
- [63] LI H, PENG Y, ZHENG J. *Dioscorea bulbifera* L.-induced hepatotoxicity and involvement of metabolic activation of furanoterpenoids[J]. Drug Metab Rev, 2020, 52(4): 568-584. DOI: 10.1080/03602532.2020.180-0724.
- [64] Endocrinology and Metabolic Diseases Committee of Integrated Traditional Chinese and Western Medicine Branch of Chinese Medical Association. Guideline for diagnosis and treatment of hyperthyroidism based on combination of disease and syndrome (2021-01-20) [J]. World Chin Med, 2021, 16(2): 193-196.
中国医师协会中西医结合医师分会内分泌与代谢病学专业委员会. 甲状腺功能亢进症病证结合诊疗指南(2021-01-20) [J]. 世界中医药, 2021, 16(2): 193-196.
- [65] Chinese Medical Association, Chinese Medical Association Publishing House, Study Group of Drug-Induced Liver Disease, Chinese Society of Hepatology, et al. Guidelines for primary diagnosis, treatment and management of drug-induced liver injury in China (2024) [J]. Chin J Gen Pract, 2024, 23(8): 813-830. DOI: 10.3760/cma.j.cn114798-20240408-00225.
中华医学会, 中华医学会杂志社, 中华医学会肝病分会药物性肝病学组, 等. 中国药物性肝损伤基层诊疗与管理指南(2024年) [J]. 中华全科医师杂志, 2024, 23(8): 813-830. DOI: 10.3760/cma.j.cn114798-20240408-00225.
- [66] SHENG QJ, DING Y, ZHANG C, et al. Analysis of clinical characteristics

- of patients with hyperthyroidism combined with liver injury[J]. Chin J Hepatol, 2021, 29(10): 967-971. DOI: 10.3760/cma.j.cn501113-202109-06-00451.
- 盛秋菊, 丁洋, 张翀, 等. 甲状腺功能亢进症合并肝损伤患者的临床特点分析[J]. 中华肝脏病杂志, 2021, 29(10): 967-971. DOI: 10.3760/cma.j.cn501113-20210906-00451.
- [67] FAN HY. Case-control study on factors influencing compliance of anti-thyroid drugs in patients with hyperthyroidism[J]. J China Prescr Drug, 2018, 16(3): 3-5. DOI: 10.3969/j.issn.1671-945X.2018.03.003.
- 樊海英. 影响甲亢患者抗甲状腺药物治疗依从性相关因素分析[J]. 中国处方药, 2018, 16(3): 3-5. DOI: 10.3969/j.issn.1671-945X.2018.03.003.
- [68] LI C, WANG KL, HU JH, et al. Clinical manifestations and early effectiveness of methimazole in patients with Graves' hyperthyroidism-related severe hepatic dysfunction[J]. Scand J Gastroenterol, 2023, 58(12): 1514-1522. DOI: 10.1080/00365521.2023.2244107.
- [69] NICULESCU DA, DUSCEAC R, GALOIU SA, et al. Serial changes of liver function tests before and during methimazole treatment in thyrotoxic patients[J]. Endocr Pract, 2016, 22(8): 974-979. DOI: 10.4158/EP161222.OR.
- [70] Chinese Society of Endocrinology, Chinese Endocrinologist Association, Chinese Society of Nuclear Medicine, et al. Guidelines for diagnosis and treatment of hyperthyroidism and thyrotoxicosis caused by other causes in China[J]. Chin J Endocrinol Metab, 2022, 38(8): 700-748. DOI: 10.3760/cma.j.cn311282-20220624-00404.
- 中华医学会内分泌学分会, 中国医师协会内分泌代谢科医师分会, 中华医学会核医学分会, 等. 中国甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南[J]. 中华内分泌代谢杂志, 2022, 38(8): 700-748. DOI: 10.3760/cma.j.cn311282-20220624-00404.
- [71] ZE YY, SHAO F, FENG XF, et al. Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves' disease[J]. BMC Endocr Disord, 2022, 22(1): 319. DOI: 10.1186/s12902-022-01242-w.
- [72] DING Y, XING JL, FANG Y, et al. ¹³¹I therapy for 345 patients with refractory severe hyperthyroidism: Without antithyroid drug pretreatment[J]. Exp Biol Med, 2016, 241(3): 290-295. DOI: 10.1177/1535-370215602784.
- [73] KAHALY GJ, BARTALENA L, HEGEDÜS L, et al. 2018 European thyroid association guideline for the management of Graves' hyperthyroidism[J]. Eur Thyroid J, 2018, 7(4): 167-186. DOI: 10.1159/000490384.
- [74] BARCZYŃSKI M. Current approach to surgical management of hyperthyroidism[J]. Q J Nucl Med Mol Imaging, 2021, 65(2): 124-131. DOI: 10.23736/S1824-4785.21.03330-6.
- [75] YANG J, LI LF, XU Q, et al. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China[J]. Thyroid, 2015, 25(3): 278-283. DOI: 10.1089/thy.2014.0350.
- [76] PAN XP, WANG HX. Clinical analysis of 14 cases of Graves disease complicated with autoimmune hepatitis[J]. Chin J Gen Pract, 2011, 9(1): 72-73.
- 潘祥坡, 王焕新. Graves病合并自身免疫性肝炎14例临床分析[J]. 中华全科医学, 2011, 9(1): 72-73.
- [77] ZHOU DH. 48 cases of chronic hepatitis B complicated with hyperthyroidism[J]. Int Med Health Guid News, 2016, 22(12): 1713-1716. DOI: 10.3760/cma.j.issn.1007-1245.2016.12.016.
- 周定辉. 慢性乙型肝炎合并甲状腺功能亢进症48例分析[J]. 国际医药卫生导报, 2016, 22(12): 1713-1716. DOI: 10.3760/cma.j.issn.1007-1245.2016.12.016.
- [78] Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus statement by the expert committee for prevention and management of liver inflammation in China[J]. Chin J Hepatol, 2014, 22(2): 94-103. DOI: 10.3760/cma.j.issn.1007-3418.2014.02.006.
- 中华医学会感染病学分会. 肝脏炎症及其防治专家共识[J]. 中华肝脏病杂志, 2014, 22(2): 94-103. DOI: 10.3760/cma.j.issn.1007-3418.2014.02.006.
- [79] DING Y, XING JL, QIU ZW, et al. Radioactive iodine therapy without recent antithyroid drug pretreatment for hyperthyroidism complicated by severe hyperbilirubinemia due to hepatic dysfunction: Experience of a Chinese medical center[J]. Endocr Pract, 2016, 22(2): 173-179. DOI: 10.4158/EP15736.OR.
- [80] LI CY, HE YQ, REN XD, et al. Effect and safety of glucocorticoids in treatment of hepatic failure: A meta analysis[J]. J Mod Med Health, 2021, 37(8): 1288-1291. DOI: 10.3969/j.issn.1009-5519.2021.08.009.
- 李春雁, 何元群, 任小丹, 等. 糖皮质激素治疗肝衰竭疗效和安全性的meta分析[J]. 现代医药卫生, 2021, 37(8): 1288-1291. DOI: 10.3969/j.issn.1009-5519.2021.08.009.
- [81] de ALMEIDA R, MCCALMON S, CABANDUGAMA PK. Clinical review and update on the management of thyroid storm[J]. Mo Med, 2022, 119(4): 366-371.
- [82] ZHENG MF, CUI SY, ZHANG W, et al. Graves' disease overlapping with chronic hepatitis B and methimazole-induced liver injury and autoimmune hepatitis: A case report[J]. BMC Gastroenterol, 2022, 22(1): 59. DOI: 10.1186/s12876-022-02133-z.
- [83] MEDHIQUB M, KHSIBA A, MAHMOUDI M, et al. Thyroid storm-induced acute liver dysfunction and portal hypertension in a patient with Graves' disease: A case report[J]. Future Sci OA, 2024, 10(1): FSO929. DOI: 10.2144/fsoa-2023-0180.
- [84] LARSEN FS. Artificial liver support in acute and acute-on-chronic liver failure[J]. Curr Opin Crit Care, 2019, 25(2): 187-191. DOI: 10.1097/MCC.0000000000000584.
- [85] BA JH, WU BQ, WANG YH, et al. Therapeutic plasma exchange and continuous renal replacement therapy for severe hyperthyroidism and multi-organ failure: A case report[J]. World J Clin Cases, 2019, 7(4): 500-507. DOI: 10.12998/wjcc.v7.i4.500.
- [86] ZHU XF, DING RR, WANG BY, et al. Iodine-131 combined with plasma exchange treatment in Graves' hyperthyroidism patients with severe liver injury whose average model for end-stage liver disease scores >20[J]. Gastro Hep Adv, 2024, 4(4): 100600. DOI: 10.1016/j.gastha.2024.100600.
- [87] FANG DZ, LI SY, ZHOU CG, et al. Comparing the prognostic impact of ¹³¹I and/or artificial liver support system on liver function failure combined with hyperthyroidism[J]. Endocr Connect, 2024, 13(11): e240330. DOI: 10.1530/EC-24-0330.
- [88] ZHANG Q, GUAN YX, XIANG TX, et al. Combination of molecular adsorbent recirculating system and radioiodine for the treatment of concurrent hyperthyroidism and severe liver dysfunction: A retrospective cohort study[J]. Endocr Pract, 2017, 23(2): 141-148. DOI: 10.4158/EP161417.OR.
- [89] TANAKA Y, UCHIDA T, YAMAGUCHI H, et al. Fulminant hepatitis and elevated levels of sIL-2R in thyroid storm[J]. Endocrinol Diabetes Metab Case Rep, 2019, 2019: 19-0078. DOI: 10.1530/EDM-19-0078.
- [90] NAGAKAWA K, SOYAMA A, HARA T, et al. Living donor liver transplantation for a patient with acute liver failure following thyroid storm: A case report[J]. Surg Case Rep, 2023, 9(1): 208. DOI: 10.1186/s40792-023-01786-6.
- [91] HAMBLETON C, BUELL J, SAGGI B, et al. Thyroid storm complicated by fulminant hepatic failure: Case report and literature review[J]. Ann Otol Rhinol Laryngol, 2013, 122(11): 679-682. DOI: 10.1177/00034894-1312201103.
- [92] de CAMPOS MAZO DF, de VASCONCELOS GBS, PEREIRA MAA, et al. Clinical spectrum and therapeutic approach to hepatocellular injury in patients with hyperthyroidism[J]. Clin Exp Gastroenterol, 2013, 6: 9-17. DOI: 10.2147/CEG.S39358.
- [93] KANDIL E, ABDEL KHALEK M, THETHI T, et al. Thyroid storm in a patient with fulminant hepatic failure[J]. Laryngoscope, 2011, 121(1): 164-166. DOI: 10.1002/lary.21183.
- [94] SIPE WEB, SU M, POSSELT A, et al. Propylthiouracil-associated liver failure presenting as probable autoimmune hepatitis in a child with Graves' disease[J]. Pediatr Transplant, 2006, 10(4): 525-528. DOI: 10.1111/j.1399-3046.2006.00487.x.